全文获取类型
收费全文 | 2886篇 |
免费 | 163篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 60篇 |
妇产科学 | 101篇 |
基础医学 | 297篇 |
口腔科学 | 46篇 |
临床医学 | 271篇 |
内科学 | 877篇 |
皮肤病学 | 53篇 |
神经病学 | 182篇 |
特种医学 | 33篇 |
外科学 | 513篇 |
综合类 | 64篇 |
一般理论 | 2篇 |
预防医学 | 166篇 |
眼科学 | 72篇 |
药学 | 187篇 |
中国医学 | 15篇 |
肿瘤学 | 108篇 |
出版年
2023年 | 28篇 |
2022年 | 73篇 |
2021年 | 112篇 |
2020年 | 53篇 |
2019年 | 87篇 |
2018年 | 106篇 |
2017年 | 56篇 |
2016年 | 86篇 |
2015年 | 73篇 |
2014年 | 113篇 |
2013年 | 121篇 |
2012年 | 207篇 |
2011年 | 209篇 |
2010年 | 108篇 |
2009年 | 113篇 |
2008年 | 175篇 |
2007年 | 184篇 |
2006年 | 163篇 |
2005年 | 176篇 |
2004年 | 166篇 |
2003年 | 133篇 |
2002年 | 127篇 |
2001年 | 41篇 |
2000年 | 31篇 |
1999年 | 38篇 |
1998年 | 24篇 |
1997年 | 18篇 |
1996年 | 23篇 |
1995年 | 16篇 |
1994年 | 10篇 |
1993年 | 11篇 |
1992年 | 26篇 |
1991年 | 23篇 |
1990年 | 19篇 |
1989年 | 9篇 |
1988年 | 22篇 |
1987年 | 9篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1982年 | 7篇 |
1980年 | 3篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1975年 | 6篇 |
1973年 | 2篇 |
1968年 | 5篇 |
1967年 | 7篇 |
1966年 | 3篇 |
排序方式: 共有3066条查询结果,搜索用时 15 毫秒
81.
82.
Bandeali SJ Kayani WT Lee VV Pan W Elayda MA Nambi V Jneid HM Alam M Wilson JM Birnbaum Y Ballantyne CM Virani SS 《The American journal of cardiology》2012,110(7):919-923
The association between preoperative use of angiotensin-converting enzyme (ACE) inhibitors and outcomes after coronary artery bypass grafting (CABG) remain controversial. Our aim was to study in-hospital outcomes after isolated CABG in patients on preoperative ACE inhibitors. A retrospective analysis of 8,889 patients who underwent isolated CABG from 2000 through 2011 was conducted. The primary outcome of interest was the incidence of major adverse events (MAEs) defined as a composite of mortality, postoperative renal dysfunction, myocardial infarction, stroke, and atrial fibrillation during index hospitalization. The secondary outcome was the incidence of individual outcomes included in MAEs. Logistic regression analyses were performed. Of 8,889 patients, 3,983 (45%) were on preoperative ACE inhibitors and 4,906 (55%) were not. Overall incidence of MAEs was 38.1% (n = 1,518) in the ACE inhibitor group compared to 33.6% (n = 1,649) in the no-ACE inhibitor group. Preoperative use of ACE inhibitors was independently associated with MAEs (odds ratio 1.13, 95% confidence interval 1.03 to 1.24), most of which was driven by a statistically significant increase in postoperative renal dysfunction (odds ratio 1.18, 95% confidence interval 1.03 to 1.36) and atrial fibrillation (odds ratio 1.15, 95% confidence interval 1.05 to 1.27). In-hospital mortality, postoperative myocardial infarction, and stroke were not significantly associated with preoperative ACE inhibitor use. Analyses performed after excluding patients with low ejection fractions yielded similar results. In conclusion, preoperative ACE inhibitor use was associated with an increased risk of MAEs after CABG, in particular postoperative renal dysfunction and atrial fibrillation. 相似文献
83.
S Yüce IO Uysal M Doğan T Ersin S Müderris 《The Journal of craniofacial surgery》2012,23(5):e396-e398
ABSTRACT: Canalicular adenomas are uncommon, benign epithelial neoplasm of the salivary glands that usually involve the upper lip and the buccal mucosa of elderly people. Differential diagnosis of the canalicular adenoma versus adenocarcinoma is important because it may result in unjustified radiotherapy or extensive and aggressive surgery. Despite the benign nature of canalicular adenomas, complete surgical removal and a regular clinical follow-up are recommended. The current study describes the diagnostic procedures, surgical management, and follow-up of a canalicular adenoma involving the palate of a 79-year-old man. 相似文献
84.
Heart disease and stroke statistics--2012 update: a report from the American Heart Association 总被引:1,自引:0,他引:1
Roger VL Go AS Lloyd-Jones DM Benjamin EJ Berry JD Borden WB Bravata DM Dai S Ford ES Fox CS Fullerton HJ Gillespie C Hailpern SM Heit JA Howard VJ Kissela BM Kittner SJ Lackland DT Lichtman JH Lisabeth LD Makuc DM Marcus GM Marelli A Matchar DB Moy CS Mozaffarian D Mussolino ME Nichol G Paynter NP Soliman EZ Sorlie PD Sotoodehnia N Turan TN Virani SS Wong ND Woo D Turner MB;American Heart Association Statistics Committee Stroke Statistics Subcommittee 《Circulation》2012,125(1):e2-e220
85.
Hohnloser SH Oldgren J Yang S Wallentin L Ezekowitz M Reilly P Eikelboom J Brueckmann M Yusuf S Connolly SJ 《Circulation》2012,125(5):669-676
86.
87.
Mariana Ferreira Leal Danielle Queiroz Calcagno André Salim Khayat Tanielly Cristina Raiol Silva José Augusto Pereira Carneiro Muniz Paulo Pimentel Assumpção Marília de Arruda Cardoso Smith Rommel Rodríguez Burbano 《Clinical and experimental medicine》2013,13(3):221-224
Despite the high incidence, the molecular events involved in intestinal-type gastric carcinogenesis remains unclear. We previously established an intestinal-type gastric carcinogenesis model in Cebus apella, a New World monkey. In the present study, we evaluated hTERT and TP53 mRNA expression, as well as their protein immunoreactivity, in normal mucosa, non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, and intestinal-type gastric cancer samples of non-human primates treated with N-methyl-nitrosourea. In addition, we evaluated the number of TP53 copies in these samples. Although hTERT immunoreactivity was only detected in gastric cancer, a continuous increase of hTERT mRNA expression was observed from non-atrophic gastritis to gastric tumors. No sample presented p53 immunoreactivity. However, we also observed a continuous decrease of TP53 mRNA expression during the sequential steps of gastric carcinogenesis. Moreover, loss of TP53 copies was observed in intestinal metaplasia and gastric cancer samples. Our study highlights that hTERT and TP53 have a key role in intestinal-type gastric cancer initiation. 相似文献
88.
89.
Graham H. Jackson Faith E. Davies Charlotte Pawlyn David A. Cairns Alina Striha Corinne Collett Anna Waterhouse John R. Jones Bhuvan Kishore Mamta Garg Cathy D. Williams Kamaraj Karunanithi Jindriska Lindsay David Allotey Salim Shafeek Matthew W. Jenner Gordon Cook Nigel H. Russell Martin F. Kaiser Mark T. Drayson Roger G. Owen Walter M. Gregory Gareth J. Morgan 《Haematologica》2021,106(7):1957
The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients with newly diagnosed multiple myeloma (n=2,042) were randomized to induction therapy with cyclophosphamide, thalidomide, and dexamethasone (CTD) or cyclophosphamide, lenalidomide, and dexamethasone (CRD). Additional intensification therapy with cyclophosphamide, bortezomib, and dexamethasone (CVD) was administered before autologous stem-cell transplantation to patients with a suboptimal response to induction therapy using a response-adapted approach. After receiving high-dose melphalan with autologous stem cell transplantation, eligible patients were further randomized to receive either lenalidomide alone or observation alone. Co-primary endpoints were progression-free survival (PFS) and overall survival (OS). The CRD regimen was associated with significantly longer PFS (median: 36 vs. 33 months; hazard ratio [HR], 0.85; 95% confidence interval [CI]: 0.75-0.96; P=0.0116) and OS (3-year OS: 82.9% vs. 77.0%; HR, 0.77; 95% CI: 0.63-0.93; P=0.0072) compared with CTD. The PFS and OS results favored CRD over CTD across all subgroups, including patients with International Staging System stage III disease (HR for PFS, 0.73; 95% CI: 0.58-0.93; HR for OS, 0.78; 95% CI: 0.56-1.09), high-risk cytogenetics (HR for PFS, 0.60; 95% CI: 0.43-0.84; HR for OS, 0.70; 95% CI: 0.42-1.15) and ultra-high-risk cytogenetics (HR for PFS, 0.67; 95% CI: 0.41-1.11; HR for OS, 0.65; 95% CI: 0.34-1.25). Among patients randomized to lenalidomide maintenance (n=451) or observation (n=377), maintenance therapy improved PFS (median: 50 vs. 28 months; HR, 0.47; 95% CI: 0.37-0.60; P<0.0001). Optimal results for PFS and OS were achieved in the patients who received CRD induction and lenalidomide maintenance. The trial was registered with the EU Clinical Trials Register (EudraCT 2009-010956-93) and ISRCTN49407852. 相似文献
90.